A Reversal for Axovant Sciences Ltd Is Not Near. Professional Options Traders Are Bullish

 A Reversal for Axovant Sciences Ltd Is Not Near. Professional Options Traders Are Bullish

In today’s session Axovant Sciences Ltd (AXON) registered an unusually high (941) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious AXON increase. With 941 contracts traded and 11824 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: AXON161021C00015000 closed last at: $0.25 or 37.5% down. About 59,195 shares traded hands. Axovant Sciences Ltd (NYSE:AXON) has risen 15.74% since March 11, 2016 and is uptrending. It has outperformed by 10.28% the S&P500.

Analysts await Axovant Sciences Ltd (NYSE:AXON) to report earnings on November, 7. They expect $-0.39 EPS, down 225.00% or $0.27 from last year’s $-0.12 per share. After $-0.38 actual EPS reported by Axovant Sciences Ltd for the previous quarter, Wall Street now forecasts 2.63% negative EPS growth.

Axovant Sciences Ltd (NYSE:AXON) Ratings Coverage

Out of 4 analysts covering Axovant Sciences (NYSE:AXON), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. $35.0 is the highest target while $8 is the lowest. The $21.67 average target is 62.69% above today’s ($13.32) stock price. Axovant Sciences has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained the shares of AXON in a report on Friday, September 25 with “Sell” rating. The stock has “Overweight” rating given by Piper Jaffray on Thursday, October 22. On Tuesday, June 7 the stock rating was initiated by Leerink Swann with “Outperform”. H.C. Wainwright initiated the stock with “Buy” rating in Friday, January 8 report.

According to Zacks Investment Research, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.”

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The company has a market cap of $1.34 billion. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. It currently has negative earnings. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB).

AXON Company Profile

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., incorporated on October 31, 2014, is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

More important recent Axovant Sciences Ltd (NYSE:AXON) news were published by: Investorplace.com which released: “Why Axovant Sciences Ltd (AXON), Jabil Circuit, Inc. (JBL) and Virgin America …” on September 22, 2016, also Fool.com published article titled: “Why Axovant Sciences Skyrocketed 56% in November”, Fool.com published: “Why Axovant Sciences Shares Are Crashing” on February 03, 2016. More interesting news about Axovant Sciences Ltd (NYSE:AXON) was released by: Benzinga.com and their article: “Axovant Sciences’ Earnings Miss Takes A Backseat To Expected Pipeline Expansion” with publication date: August 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment